IQV
NYSEIQVIA Holdings Inc.
Price$206.22-4.94 (-2.34%)
01:30 PM07:45 PM
News · 26 weeks81-25%
2026-01-182026-07-12
Mix3590d
- Insider16(46%)
- SEC Filings8(23%)
- Other8(23%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Wims Morris Leslie4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Goggins Colleen A4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Fasano Jim4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Danhakl John G4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- PRIQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United StatesIQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, shared recommendations for strengthening the United States as a leading destination for early clinical development during the U.S. House Committee on Energy and Commerce Subcommittee on Health hearing, "Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development." Recommendations were presented by Dr. Cynthia Verst, president, Design and Delivery Innovation, Research and Development Solutions at IQVIA, who highlighted the importance of making the path from scientific discovery
- PRIQVIA to Announce Second-Quarter 2026 Results on July 28, 2026IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2026 financial results before the market opens on Tuesday, July 28, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http://ir.iqvia.com. To
- ANALYSTIQVIA downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded IQVIA from Overweight to Equal-Weight and set a new price target of $200.00
- PRWiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value ChainInsights drawn from executive Summit hosted by Wiley and IQVIA with leaders from pharma, academia, health systems, technology companies and more Wiley (NYSE:WLY) and IQVIA (NYSE:IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615344569/en/ The report summarizes insights from The Summit — an invitation-only, two-day working session co-hosted by Wiley
- SECIQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
- SECSEC Form 8-K filed by IQVIA Holdings Inc.8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
- PRIQVIA Announces Pricing of Senior NotesIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of €950,000,000 in aggregate principal amount of senior notes due 2033 (the "Notes"). The proceeds from the Notes offering will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the Notes offering. The Notes will bear interest at a rate of 4.625% per annum and will pay interest semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2026. The Notes will mature on June 15, 2033, unless earlier repurchased or redeemed in accordance with their terms. The issuance of
- SECSEC Form 8-K filed by IQVIA Holdings Inc.8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
- PRIQVIA Announces Offering of Senior NotesIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise €950,000,000 through an offering of senior notes due 2033 (the "Notes"). The proceeds from the Notes offering will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to market and other customary conditions. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer,
- PRIQVIA CEO to Speak at Jefferies Global Healthcare ConferenceIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:20 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the
- PRIQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled CapabilitiesIQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. Kexing Biopharm (Stock Code: 688136.SH) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations. The collaboration is designed to support Kexing's global expansion by bringing together IQVIA's end-to-end capabilities across the development lifecycle. By aligning clinical dev
- INSIDERSEC Form 4 filed by Director Wims Morris Leslie4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Goggins Colleen A4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Fasano Jim4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- INSIDERSEC Form 4 filed by Director Danhakl John G4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
- SECSEC Form 8-K filed by IQVIA Holdings Inc.8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
- PRIQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase AuthorizationIQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that its board of directors authorized the repurchase of an additional $2 billion of IQVIA's common stock under IQVIA's existing equity repurchase program (the "Repurchase Program"), bringing the total remaining authorization to $3.2 billion. The Repurchase Program does not obligate IQVIA to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. The timing and amount of repurchases are determined by IQVIA's managem
- PRIQVIA CFO to Speak at Bank of America Health Care Conference 2026IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Mike Fedock, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas, NV on Wednesday, May 13, 2026, at 1:40 p.m. ET (10:40 a.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services,
- SECSEC Form 10-Q filed by IQVIA Holdings Inc.10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)
- SECIQVIA Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
- PRIQVIA Reports First-Quarter 2026 ResultsRevenue of $4,151 million, up 8.4% year-over-year GAAP Net Income of $274 million, Adjusted EBITDA of $932 million GAAP Diluted Earnings per Share of $1.61, Adjusted Diluted Earnings per Share of $2.90 Commercial Solutions Revenue of $1,754 million, up 11.6% reported year-over-year R&D Solutions Revenue of $2,397 million, up 6.2% reported year-over-year R&D Solutions contracted backlog of $34.2 billion, R&D Solutions Net New Bookings of $2.5 billion Operating Cash Flow of $618 million; Free Cash Flow of $491 million, up 15% year-over-year, representing 100% of Adjusted Net Income Repurchased $552 million of IQVIA common stock Reaffirming full-year 2026 guidance for
IQV FAQ
7 questionsWhat does IQVIA Holdings Inc. do?
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision...Where does IQV stock trade?
IQVIA Holdings Inc. (IQV) is listed on NYSE.What sector and industry is IQV in?
IQVIA Holdings Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did IQVIA Holdings Inc. go public?
IQVIA Holdings Inc. (IQV) completed its IPO in 2013.What are analysts saying about IQV?
IQVIA Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight on 2026-06-17.What companies are similar to IQV?
Notable peers in the same industry include JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), AZN (AstraZeneca PLC), DHR (Danaher Corporation), MDT (Medtronic plc.). Compare IQV side-by-side with any of them on Quantisnow.How can I track IQV on Quantisnow?
Quantisnow aggregates IQVIA Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IQV to receive live email and push alerts on every new disclosure.